This study was funded by contract NO1MH80001 from the National Institute of Mental Health.
Dr. Sylvia was a shareholder in Concordant Rater Systems and serves as a consultant for United Biosource Corporation and Clintara. She receives royalties from New Harbinger. Dr. Iosifescu is a consultant for CNS Response and Servier. Dr. Friedman receives grant support from AstraZeneca Pharmaceuticals, Medtronics, Novartis, Repligen, Roche, St. Jude Medical, and Takeda. He receives royalties from Springer. Dr. Ketter receives research support from AstraZeneca, Cephalon, Eli Lilly and Company, Pfizer, and Sunovion Pharmaceuticals. He receives consultant fees from Allergan, Avanir Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon, Forest Pharmaceuticals, Janssen Pharmaceutica Products, Merck & Co., Sunovion, and Teva Pharmaceuticals. He has received lecture honoraria from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, and Otsuka Pharmaceuticals and receives publication royalties from American Psychiatric Publishing. In addition, Dr. Ketter’s spouse is an employee of and holds stock in Janssen. Dr. Reilly-Harrington receives royalties from Oxford University Press and the American Psychological Association and serves as a consultant for United Biosource Corporation. Dr. Leon served on independent data and safety monitoring boards for AstraZeneca, Sunovion, and Pfizer. He served as a consultant and advisor to MedAvante and Roche and had equity in MedAvante. Dr. Calabrese receives research funding or grants from the following private industries or nonprofit funds: Brain and Behavior Research Foundation (formerly NARSAD), Cleveland Foundation, and Stanley Medical Research Institute; he receives research grants from Abbott, AstraZeneca, Cephalon, GlaxoSmithKline, Janssen, Eli Lilly, and Lundbeck; he serves on the advisory boards of Abbott, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Forest, France Foundation, GlaxoSmithKline, Janssen, NeuroSearch, OrthoMcNeil, Repligen, Schering-Plough, Servier, Solvay/Wyeth, Takeda, and Supernus Pharmaceuticals; and he reports continuing medical education activities with AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, Schering-Plough, and Solvay/Wyeth. Dr. Ostacher has served as a consultant for Alexza Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Janssen, Otsuka, and Sunovion. Dr. Thase has, during the past three years, been an advisor or consultant to Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Lundbeck, MedAvante, Merck, Mylan, Neuronetics, Otsuka, Pamlab, Pfizer, PharmaNeuroboost, Roche, Shire, Sunovion, Takeda, and Teva. During the same time frame, he received honoraria for continuing education talks that were supported by AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer, and he has received research grants from Alkermes, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Otsuka, PharmaNeuroboost, and Roche. Dr. Nierenberg is a consultant for Abbott Laboratories, AstraZeneca, Basilea, BrainCells Inc., Brandeis University, Bristol-Myers Squibb, Cephalon, Corcept, Eli Lilly, Forest, Genaissance, GlaxoSmithKline, Innapharma, Janssen, Jazz Pharmaceuticals, Lundbeck, Merck, Novartis, PamLabs, Pfizer, PGx Health, Ridge Diagnostics, Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, and Teva. He is a stakeholder in Appliance Computing, Inc. (MindSite); Brain Cells, Inc.; and InfoMed (potential share of income). He receives research support from Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cyberonics, Elan, Forest Pharmaceuticals, GlaxoSmithKline, Janssen, Lichtwer Pharma, Eli Lilly, Mylan, Pamlabs, Pfizer, Shire, Stanley Foundation, and Wyeth-Ayerst. Honoraria include MGH Psychiatry Academy. He receives other income from CRICO for legal case reviews, from MBL Publishing for past services as Editor-in-Chief of CNS Spectrums, from Slack Inc. for services as associate editor of Psychiatric Annals, and from Belvoir Publications for serving on the editorial board of Mind Mood Memory. He has joint copyright ownership with MGH for the Structured Clinical Interview for MADRS and Clinical Positive Affect Scale. He receives additional honoraria from ADURS, American Society for Clinical Psychopharmacology, AstraZeneca, Biomedical Development, Brandeis University, East Asian Bipolar Forum, Eli Lilly, Forest, Harold Grinspoon Charitable Foundation, Health New England, International Society for Bipolar Disorder, Janssen, Mid-Atlantic Permanente Research Institute, University of Pisa, University Texas Southwest at Dallas, University of Wisconsin–Madison, Up-to-Date, and Zucker Hillside Hospital. The other authors report no competing interests.